The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression
Abstract
BACKGROUND: Sustained suppression of the human immunodeficiency virus (HIV) type 1 RNA load with the use of highly active antiretroviral therapy (HAART) results in immunologic improvement, but it is not clear whether the CD4(+) cell count increases to normal levels or whether it reaches a less-than-normal plateau. We characterized the increase in the CD4(+) cell count in patients in clinical practice who maintained sustained viral suppression for up to 6 years. METHODS: All patients were from the Johns Hopkins HIV Clinical Cohort, a longitudinal observational study of patients receiving primary HIV care in Baltimore, Maryland, who were observed for >1 year while receiving HAART and who had sustained suppression of the HIV RNA load at <400 copies/mL. We analyzed annual change in the CD4(+) cell count for up to 6 years after the start of HAART, stratified by baseline CD4(+) cell counts of < or =200, 201-350, >350 cells/microL, and we assessed the development of clinical events (death and new acquired immunodeficiency syndrome-defining illness) by Kaplan-Meier analysis. RESULTS: A total of 655 patients were observed for a median of 46 months (range, 13-72 months). The median change from baseline to most recent CD4(+) cell count was +274 cells/microL, with 92% of patients having an increase in CD4(+) cell count. By 6 years, the median CD4(+) cell count was 493 cells/microL among patients with baseline CD4(+) cell counts < or =200 cells/microL, 508 cells/microL among those with baseline CD4(+) cell counts of 201-350 cells/microL, and 829 cells/microL among those with baseline CD4(+) cell counts >350 cells/microL. In addition to baseline CD4(+) cell count, injection drug use and older age were associated with a lesser CD4(+) cell count response, and duration of therapy was associated with a greater CD4(+) cell count response. CONCLUSION: Only patients with baseline CD4(+) cell counts >350 cells/microL returned to nearly normal CD4(+) cell counts after 6 years of follow-up. Significant increases were observed in all CD4(+) cell count strata during the first year, but there was a lower plateau CD4(+) cell count at lower baseline CD4(+) cell strata. These data suggest that waiting to start HAART at lower CD4(+) cell counts will result in the CD4(+) cell count not returning to normal levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Pakker, N. G., Notermans, D. W., De Boer, R. J., Roos, M. T. L., Wolf, F. D., Hill, A., Leonard, J. M., Danner, S. A., Miedema, F., & Schellekens, P. T. A. (1998) · Nature Medicine · doi:10.1038/nm0298-208 · Cited by 701
Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002) · AIDS · doi:10.1097/00002030-200203290-00012 · Cited by 320
Self-citationHunt, P. W., Deeks, S. G., Rodriguez, B., Valdez, H., Shade, S. B., Abrams, D. I., Kitahata, M. M., Krone, M., Neilands, T. B., Brand, R. J., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00009 · Cited by 273
Garc??a, F., de Lazzari, E., Plana, M., Castro, P., Mestre, G., Nomdedeu, M., Fumero, E., Mart??nez, E., Mallolas, J., Blanco, J. L., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200406010-00007 · Cited by 193
Smith, C. J., Sabin, C. A., Youle, M. S., Loes, S. K., Lampe, F. C., Madge, S., Cropley, I. M., Johnson, M. A., & Phillips, A. N. (2004) · The Journal of Infectious Diseases · doi:10.1086/425075 · Cited by 157
Moore, R. D. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199801001-00011 · Cited by 154
Self-citationTarwater, P. M., Margolick, J. B., Jin, J., Phair, J. P., Detels, R., Rinaldo, C. R., Giorgi, J. V., & Muñoz, A. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200106010-00012 · Cited by 115
Pulido, F., Arribas, J. R., Mir, J. M., Costa, M. A. A., ́lez, J. G., Rubio, R., a, J. M. P., Torralba, M., Loncà, M., Lorenzo, A., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200404010-00003 · Cited by 64
Michael, C. G., Kirk, O., Mathiesen, L., & Nielsen, S. D. (2002) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540110076930 · Cited by 16
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Self-citationHammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Jiang, W., Lederman, M. M., Hunt, P., Sieg, S. F., Haley, K., Rodriguez, B., Landay, A., Martin, J., Sinclair, E., Asher, A. I., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597476 · Cited by 591
Risk of Human Papillomavirus–Associated Cancers Among Persons With AIDS
Chaturvedi, A. K., Madeleine, M. M., Biggar, R. J., & Engels, E. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp205 · Cited by 523
Metadata
- Authors
- Moore, R. D., & Keruly, J. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02-01
- Volume
- 44
- Issue
- 3
- Pages
- 441-446
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2106164053
- Cited by
- 415
- References
- 10
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.